2012-10-05 16:16:16 - New Pharmaceuticals market report from Global Markets Direct: "Multiple Sclerosis - Pipeline Review, H2 2012"
Global Markets Direct's, 'Multiple Sclerosis - Pipeline Review, Global Markets Direct's, 'Multiple Sclerosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. Multiple Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/468348_multiple_sclerosis_pipeline_review_h2 ..
Note*: Certain sections
in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
* A snapshot of the global therapeutic scenario for Multiple Sclerosis.
* A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Multiple Sclerosis Overview
An Overview of Pipeline Products for Multiple Sclerosis
Multiple Sclerosis Therapeutics under Development by Companies
Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Multiple Sclerosis Therapeutics - Products under Development by Companies
Multiple Sclerosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Multiple Sclerosis Therapeutics Development
Baxter International Inc.
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Eli Lilly and Company
Daiichi Sankyo Company, Ltd
Cytokine PharmaSciences, Inc.
Apitope International NV
Acorda Therapeutics, Inc.
Astellas Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Elan Corporation, plc
Glenmark Pharmaceuticals Ltd.
Mitsubishi Tanabe Pharma Corporation
Ono Pharmaceutical Co., Ltd.
Rigel Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Vertex Pharmaceuticals Incorporated
Zydus Cadila Healthcare Limited
Paratek Pharmaceuticals, Inc.
BrainStorm Cell Therapeutics Inc.
Genesis Research and Development Corporation Ltd.
Hemispherx Biopharma, Inc.
Hollis-Eden Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Idera Pharmaceuticals, Inc.
PROLOR Biotech, Inc.
MultiCell Technologies, Inc.
Nutra Pharma Corporation
Opexa Therapeutics, Inc.
Critical Outcome Technologies Inc.
Accentia Biopharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Zenotech Laboratories Limited
RegeneRx Biopharmaceuticals, Inc.
ProMetic Life Sciences Inc.
Hanall Pharmaceutical Co., Ltd.
Cytos Biotechnology AG
Pluristem Therapeutics Inc.
Sareum Holdings plc
Santhera Pharmaceuticals Holding AG
Transgene Biotek Ltd
Shenzhen Beike Biotechnology Co., Ltd.
Stem Cell Therapeutics Corp.
Digna Biotech, S.L.
Bayhill Therapeutics, Inc.
Phenex Pharmaceuticals AG
Hutchison MediPharma Limited
Artielle ImmunoTherapeutics, Inc.
Affectis Pharmaceuticals AG
ProtAffin Biotechnologie AG
Coronado Biosciences, Inc.
Q Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Innate Therapeutics Limited
Deciphera Pharmaceuticals, LLC
MSM Protein Technologies, Inc.
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.